statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of pharma majors Eli Lilly and Novo Nordisk witnessed some selling pressure in Wednesday’s pre-market session after Swiss multinational firm Roche disclosed positive data about its weight loss drug. Although both shares fell nearly 3% in pre-market trading, retail investors have shrugged off the negative impact on Eli Lilly and Novo Nordisk with the sentiment meter for both these stocks trending in the neutral to bullish territory.Roche said in a statement that after four weeks of treatment, its once-daily oral molecule CT-996, developed for treating both type 2 diabetes and obesity, demonstrated clinically meaningful weight loss of -7.3%. The company said that based on the study data, CT-996 is expected to be used not only as a therapy for achieving glycaemic control and inducing weight loss but also for oral weight maintenance therapy following weight loss induced by injectables.Following the announcement, shares of Roche Holdings rose over 7% in pre-market trading on Wednesday.The positive news from the competition failed to invoke much negative sentiment from retail investors for Eli Lilly and Novo Nordisk. The Stocktwits sentiment meter for Eli Lily was trending in bullish territory (73/100) while it was hovering in the neutral zone for Novo Nordisk.<figure class="image"><img style="aspect-ratio:773/218;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_5b928b274b.png" alt="Bullish retail sentiment on Eli Lilly" width="773" height="218"><figcaption>Bullish retail sentiment on Eli Lilly</figcaption></figure>With Roche’s latest disclosure, competition appears to be intensifying in the weight loss drug market. Eli Lilly’s drug Zepbound was approved by the US Food and Drug Administration (USFDA) in November 2023 while Novo Nordic’s Wegovy was approved in the US in March this year.<figure class="image"><img style="aspect-ratio:771/215;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Novo_Nordisk_eced03aed1.png" alt="Retail sentiment for Novo Nordisk in neutral zone" width="771" height="215"><figcaption>Retail sentiment for Novo Nordisk in neutral zone</figcaption></figure>Regarding stock prices, Eli Lilly is trading at a price-to-earnings ratio of 141, whereas Novo Nordisk shares are trading at a multiple of 48.5x. Meanwhile, Roche Holdings ADR is currently trending at a relatively cheaper multiple of 16x. Still, retail investors appear to be looking past the elevated valuations in hopes that these companies can grow into them over time.&nbsp;&nbsp;

How Retail Investors Reacted To Eli Lilly And Novo Nordisk Share Price Declines After Roche’s Positive Drug Data

Despite some selling pressure on Eli Lilly and Novo Nordisk shares, retail investors have shrugged off the intensifying competition in the weight management drug segment. However, valuations could be something to look out for.

Equity

Despite some selling pressure on Eli Lilly and Novo Nordisk shares, retail investors have shrugged off the intensifying competition in the weight management drug segment. However, valuations could be something to look out for.


Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

Roche Holdings AG ADR

Volume	2.78M
52-Wk High	$40.80
52-Wk Low	$29.20

RHHBY Roche Holdings AG ADR

About

Feed

News

Earnings

Fundamentals